Kardiologie up2date, Table of Contents Kardiologie up2date 2013; 09(04): 271-275DOI: 10.1055/s-0033-1359202 Hotline – Koronare Herzerkrankung und Atherosklerose © Georg Thieme Verlag KG Stuttgart · New York Der vulnerable Patient mit chronischer Niereninsuffizienz Nikolaus Marx , Jürgen Floege Recommend Article Abstract Buy Article All articles of this category Abstract Patients with chronic kidney disease (CKD) exhibit an increased risk to develop cardiovascular events. Sudden cardiac death is the main reason for the increased cardiovascular mortality in this patient population. Our current understanding suggests that patients with CKD are vulnerable patients and that the increased risk of these patients is determined by the 3 components of the vulnerable blood, the vulnerable vessel and the vulnerable myocardium. The following review discusses the different pathophysiological aspects of the vulnerable patient with CKD and elucidates therapeutic options to reduce the risk for sudden cardiac death in this patient population. Full Text References Literatur 1 USRDS. Causes of death. United States Renal Data System. Am J Kidney Dis 1997; 30: 107-117 2 Chugh SS. Early identification of risk factors for sudden cardiac death. Nat Rev Cardiol 2010; 7: 318-326 3 Herzog CA, Mangrum JM, Passman R. Sudden cardiac death and dialysis patients. Semin Dial 2008; 21: 300-307 4 Wanner C, Krane V, Marz W et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353: 238-248 5 de Bie MK, Buiten MS, Rabelink TJ et al. How to reduce sudden cardiac death in patients with renal failure. Heart 2012; 98: 335-341 6 Green D, Roberts PR, New DI et al. Sudden cardiac death in hemodialysis patients: an in-depth review. Am J Kidney Dis 2011; 57: 921-929 7 Nakano T, Ninomiya T, Sumiyoshi S et al. Association of kidney function with coronary atherosclerosis and calcification in autopsy samples from Japanese elders: the Hisayama study. Am J Kidney Dis 2010; 55: 21-30 8 Sipahioglu MH, Kucuk H, Unal A et al. Impact of arterial stiffness on adverse cardiovascular outcomes and mortality in peritoneal dialysis patients. Perit Dial Int 2012; 32: 73-80 9 Steering Committee of the Physicians’ Health Study Research Group. Physicians’ health study: aspirin and primary prevention of coronary heart disease. N Engl J Med 1989; 321: 1825-1828 10 Mark PB, Johnston N, Groenning BA et al. Redefinition of uremic cardiomyopathy by contrast-enhanced cardiac magnetic resonance imaging. Kidney Int 2006; 69: 1839-1845 11 McIntyre CW. Haemodialysis-induced myocardial stunning in chronic kidney disease – a new aspect of cardiovascular disease. Blood Purif 2010; 29: 105-110 12 Burton JO, Jefferies HJ, Selby NM et al. Hemodialysis-induced repetitive myocardial injury results in global and segmental reduction in systolic cardiac function. Clin J Am Soc Nephrol 2009; 4: 1925-1931 13 Burton JO, Jefferies HJ, Selby NM et al. Hemodialysis-induced cardiac injury: determinants and associated outcomes. Clin J Am Soc Nephrol 2009; 4: 914-920 14 Amann K, Rychlik I, Miltenberger-Milteny G et al. Left ventricular hypertrophy in renal failure. Kidney Int Suppl 1998; 68: 78-85 15 Masuo K, Mikami H, Ogihara T et al. Hormonal mechanisms in blood pressure reduction during hemodialysis in patients with chronic renal failure. Hypertens Res 1995; 18: 201-203 16 Park J, Campese VM, Nobakht N et al. Differential distribution of muscle and skin sympathetic nerve activity in patients with end-stage renal disease. J Appl Physiol 2008; 105: 1873-1876 17 Dhein S, Rohnert P, Markau S et al. Cardiac beta-adrenoceptors in chronic uremia: studies in humans and rats. J Am Coll Cardiol 2000; 36: 608-617 18 Saravanan P, Davidson NC. Risk assessment for sudden cardiac death in dialysis patients. Circ Arrhythm Electrophysiol 2010; 3: 553-559 19 Genovesi S, Valsecchi MG, Rossi E et al. Sudden death and associated factors in a historical cohort of chronic haemodialysis patients. Nephrol Dial Transplant 2009; 24: 2529-2536 20 Ganesh SK, Stack AG, Levin NW et al. Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001; 12: 2131-2138 21 Drechsler C, Verduijn M, Pilz S et al. Vitamin D status and clinical outcomes in incident dialysis patients: results from the NECOSAD study. Nephrol Dial Transplant 2011; 26: 1024-1032 22 Drechsler C, Krane V, Winkler K et al. Changes in adiponectin and the risk of sudden death, stroke, myocardial infarction, and mortality in hemodialysis patients. Kidney Int 2009; 76: 567-575 23 Parekh RS, Plantinga LC, Kao WH et al. The association of sudden cardiac death with inflammation and other traditional risk factors. Kidney Int 2008; 74: 1335-1342 24 Bleyer AJ, Hartman J, Brannon PC et al. Characteristics of sudden death in hemodialysis patients. Kidney Int 2006; 69: 2268-2273 25 Bleyer AJ, Russell GB, Satko SG. Sudden and cardiac death rates in hemodialysis patients. Kidney Int 1999; 55: 1553-1559 26 Karnik JA, Young BS, Lew NL et al. Cardiac arrest and sudden death in dialysis units. Kidney Int 2001; 60: 350-357 27 Perl J, Chan CT. Timing of sudden death relative to the hemodialysis procedure. Nat Clin Pract Nephrol 2006; 2: 668-669 28 McMurray JJ, Adamopoulos S, Anker SD et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012; 33: 1787-1847 29 Cuculich PS, Sanchez JM, Kerzner R et al. Poor prognosis for patients with chronic kidney disease despite ICD therapy for the primary prevention of sudden death. Pacing Clin Electrophysiol 2007; 30: 207-213 30 Maduell F, Moreso F, Pons M et al. High-efficiency postdilution online hemodiafiltration reduces all-cause mortality in hemodialysis patients. J Am Soc Nephrol 2013; 24: 487-497 31 Ok E, Asci G, Toz H et al. Mortality and cardiovascular events in online haemodiafiltration (OL-HDF) compared with high-flux dialysis: results from the Turkish OL-HDF Study. Nephrol Dial Transplant 2013; 28: 192-202 32 Brophy JM, Joseph L, Rouleau JL. Beta-blockers in congestive heart failure. A Bayesian meta-analysis. . Ann Intern Med 2001; 134: 550-560 33 Freemantle N, Cleland J, Young P et al. beta Blockade after myocardial infarction: systematic review and meta regression analysis. Bmj 1999; 318: 1730-1737 34 Cice G, Ferrara L, D'Andrea A et al. Carvedilol increases two-year survivalin dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial. J Am Coll Cardiol 2003; 41: 1438-1444 35 Badve SV, Roberts MA, Hawley CM et al. Effects of beta-adrenergic antagonists in patients with chronic kidney disease: a systematic review and meta-analysis. J Am Coll Cardiol 2011; 58: 1152-1161 36 Cice G, Di Benedetto A, D’Isa S et al. Effects of telmisartan added to Angiotensin-converting enzyme inhibitors on mortality and morbidity in hemodialysis patients with chronic heart failure a double-blind, placebo-controlled trial. J Am Coll Cardiol 2010; 56: 1701-1708 37 Korantzopoulos P, Liu T, Li L et al. Implantable cardioverter defibrillator therapy in chronic kidney disease: a meta-analysis. Europace 2009; 11: 1469-1475
